Greenphire, provider of payment technologies for the clinical trials industry, announced that a top 5 pharmaceutical company will use its ClinCard Technology Platform in a large, Phase III clinical trial. The trial will include over 1,000 patients across 6 countries and is expected to last over five years.
The ClinCard system aims to allow the sponsor to execute quick and accurate payments to patients globally in 4 different currencies and will reduce the administrative burden on sites by replacing traditional manual processes with automated electronic payments. In previous studies, ClinCard has decreased time spent on administrative tasks related to patient payments by up to 90% and has reduced associated costs by up to 60%. In addition to reducing time and costs for clinical research sites, the ClinCard was selected for its proven ability to increase patient retention.
“By combining real-time patient payments in local currencies with automated patient messaging systems, the ClinCard system has been shown to increase patient retention by up to 11.7%, a particularly important consideration in a long-term study such as this,” said Sam Whitaker, Greenphire’s CEO and co-founder. “I am pleased that the ClinCard solution can help to ensure the success of this study and that Greenphire’s vision for automated payment processes is increasingly accepted within the industry as a way to reduce administration, costs, and risk in complex clinical trials.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.